Halozyme Therapeutics | HALO - Операционный доход

Биржевая цена
68.19
Изменение за день
1.11 1.65%
Ежемесячно
2.57%
Ежегодный
13.23%
Q2 прогноз
62.55




Операционный доход Изменить Дата
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.96B 464M 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Cara Therapeutics USD -5.94M 3.55M 2025-09
Cytokinetics USD -178.37M 11.61M 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
MannKind USD -69.24M 28.19M 2025-12
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12